ProKidney Corp. Class A Ordinary Shares — Grafico, Quotazione e Notizie (NASDAQ:PROK) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 576.6597 M
Employee 231
Founded 2015
CEO N/A
Website www.prokidney.com
Headquarter Cayman Islands
FIGI BBG0119BQ2Y2
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

576.66 M Capitalizzazione di mercato

Rapporto prezzo/utili

-4.31

Rapporto prezzo/fatturato

335.98

Notizie

ProKidney nomina Greg Madison come chief commercial officer

BofA conferma rating Underperform su ProKidney con target a $1

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright avvia copertura su ProKidney con rating Buy e target di $12

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual